Cardiac Dimensions Takes on Abbott and Edwards in FMR Market

Cardiac Dimensions said it has all the makings of a dominant competitor in the functional mitral regurgitation (FMR) market.  And the Kirkland WA-based company isn’t letting the fact that it’s the smallest of three firms competing in the FMR space hinder its path in obtaining a top spot. On Thursday, Cardiac Dimensions announced it had reached a significant milestone, by closing on a $39 million Series B round in an effort to build clinical evidence for its Carillon Mitral Contour System. The funding will be used to help continue the 450-patient CARILLON Trial Pivotal Study and complete the follow-up and publication of the landmark randomized, double-blinded REDUCE FMR global study. The U.S. trial will help the company obtain a PMA for the Carillon Mitral Contour System. The firm  has CE mark for the device.  Cardiac Dimensions said the trials were unique because none of its competitors have a double-blinded study assessing FMR treatment. “We have created and designed a technology that helps with an annuloplasty approach to give assistant to patients with functional mitral regurgitation,” Gregory Casciaro, president and CEO of Cardiac Dimensions. “We do it differently than some of the competition out there in that ours is called an indirect annuloplasty- meaning that we effectively try to treat those patients on their annulus but never directly.” The company said the Carillon Mitral Contour System is introduced through a large vein from the right side of the p...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news